Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alivus Life Sciences's Enterprise Value is ₹126,875 Mil.
Alivus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Alivus Life Sciences's EV-to-FCF for today is .
The historical rank and industry rank for Alivus Life Sciences's EV-to-FCF or its related term are showing as below:
BOM:543322'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 49.11
Current: 49.11
During the past 8 years, the highest EV-to-FCF of Alivus Life Sciences was 49.11. The lowest was 0.00. And the median was 0.00.
BOM:543322's EV-to-FCF is ranked worse than 74.04% of 570
companies
in the Drug Manufacturers industry
Industry Median: 20.645
vs BOM:543322: 49.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alivus Life Sciences (BOM:543322) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alivus Life Sciences's PE Ratio (TTM) for today is calculated as:
Alivus Life Sciences's share price for today is ₹1095.45.
Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹45.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alivus Life Sciences EV-to-FCF Related Terms
Alivus Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's EV-to-FCF falls into.
Alivus Life Sciences's current Enterprise Value is ₹126,875 Mil.
Alivus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Alivus Life Sciences (BOM:543322) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,095.45 is trading 7.2% above its estimated GF Value™ of ₹1,021.50.
GuruFocus considers Alivus Life Sciences to be Fairly Valued.
Key valuation signals for BOM:543322:
EV-to-FCF:
GF Value™: ₹1,021.50 vs. price of ₹1,095.45 (7.2% above fair value)
No single metric tells the full story. See the BOM:543322 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score
Get the complete analysis for BOM:543322
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543322 has been successfully added to your 
